Absorption and elimination of trivalent and hexavalent chromium in humans following ingestion of a bolus dose in drinking water

被引:118
作者
Kerger, BD [1 ]
Paustenbach, DJ [1 ]
Corbett, GE [1 ]
Finley, BL [1 ]
机构
[1] MCLAREN HART CHEMRISK,ALAMEDA,CA 94501
关键词
D O I
10.1006/taap.1996.0271
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
These studies investigate the magnitude and valence state of chromium absorbed following plausible drinking water exposures to chromium(VI). Four adult male volunteers ingested a single dose of 5 mg Cr (in 0.5 liters deionized water) in three chromium mixtures: (1) Cr(III) chloride (CrCl3), (2) potassium dichromate reduced with orange juice (Cr(III)-OJ); and (3) potassium dichromate [Cr(VI)], Blood and urine chromium levels were followed for 1-3 days prior to and up to 12 days after ingestion, The three mixtures showed quite different pharmacokinetic patterns. CrCl3 was poorly absorbed (estimated 0.13% bioavailability) and rapidly eliminated in urine (excretion half-life, similar to 10 hr), whereas Cr(III)-OJ was absorbed more efficiently (0.60% bioavailability) but more slowly (half-life, similar to 17 hr), and Cr(VI) had the highest bioavailability (6.9%) and the longest half-life (similar to 39 hr). All three chromium mixtures caused temporary elevations in red blood cell (RBC) and plasma chromium concentrations, but the magnitude and duration of elevation showed a clear trend (Cr(VI) > Cr(III)-OJ > CrCl3), The data suggest that nearly all the ingested Cr(VI) was reduced to Cr(III) before entering the bloodstream based on comparison to RBC and plasma chromium patterns in animals exposed to high doses of Cr(VI), These findings support our prior work which suggests that water-soluble organic complexes of Cr(III) formed during the reduction of Cr(VI) in vivo explain the patterns of blood uptake and urinary excretion in humans at drinking water concentrations of 10 mg/liter or less. (C) 1996 Academic Press, Inc.
引用
收藏
页码:145 / 158
页数:14
相关论文
共 52 条
[1]  
Aitio A., 1988, BIOL MONITORING TOXI, P369, DOI [10.1007/978-1-4613-0961-1_15, DOI 10.1007/978-1-4613-0961-1_15]
[2]  
ANDERSON RA, 1994, RISK ASSESSMENT OF ESSENTIAL ELEMENTS, P187
[3]  
ANDERSON RA, 1996, FUNDAM APPL TOXICOL, V30, P299
[4]  
[Anonymous], NEWER TRACE ELEMENTS
[5]   CHRONIC TOXICITY STUDIES .3. CHRONIC TOXICITY OF CADMIUM AND CHROMIUM IN DOGS [J].
ANWAR, RA ;
BYERRUM, RU ;
HOPPERT, CA ;
LANGHAM, RF ;
ALFREDSON, BV .
ARCHIVES OF ENVIRONMENTAL HEALTH, 1961, 3 (04) :456-&
[6]  
BORNEFF J, 1968, ARCH HYG BAKTERIOL, V152, P45
[7]   CHROMIUM(VI) REDUCING CAPACITY OF ASCORBIC-ACID AND OF HUMAN PLASMA INVITRO [J].
CAPELLMANN, M ;
BOLT, HM .
ARCHIVES OF TOXICOLOGY, 1992, 66 (01) :45-50
[8]  
CHUTE SM, 1996, FUNDAM APPL TOXICOL, V30, P7
[9]   DISTRIBUTION OF CHROMIUM WITHIN CELLS OF THE BLOOD [J].
COOGAN, TP ;
SQUIBB, KS ;
MOTZ, J ;
KINNEY, PL ;
COSTA, M .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1991, 108 (01) :157-166
[10]   CIRCADIAN REDUCTION OF CHROMIUM IN THE GASTRIC ENVIRONMENT [J].
DEFLORA, S ;
BADOLATI, GS ;
SERRA, D ;
PICCIOTTO, A ;
MAGNOLIA, MR ;
SAVARINO, V .
MUTATION RESEARCH, 1987, 192 (03) :169-174